Beryl Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE415H01017
  • NSEID:
  • BSEID: 524606
INR
24.70
0.27 (1.11%)
BSENSE

Nov 20

BSE+NSE Vol: 4.13 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Beryl Drugs
Colinz Labs
Unjha Formul.
Brawn Biotech
Desh Rakshak
Genomic Valley
Starsource Multi
Ortin Global
Dipna Pharmachem
Saroja Pharma In
Ganga Pharma.
Why is Beryl Drugs Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.13%
  • Poor long term growth as Net Sales has grown by an annual rate of 8.32% and Operating profit at 9.86% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.93
2
Positive results in Sep 26
  • NET SALES(Latest six months) At Rs 14.23 cr has Grown at 43.02%
  • PAT(9M) Higher at Rs 0.84 Cr
3
Stock is technically in a Bullish range
  • The technical trend has improved from Mildly Bullish on 16-Nov-26 and has generated -1.55% returns since then
  • Multiple factors for the stock are Bullish like MACD, Bollinger Band and KST
4
With ROCE of 7.3, it has a Very Attractive valuation with a 1.2 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 8.57%, its profits have risen by 44% ; the PEG ratio of the company is 0.1
5
Majority shareholders : Non Institution
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Beryl Drugs should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Beryl Drugs for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Beryl Drugs
8.57%
0.13
67.24%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
8.32%
EBIT Growth (5y)
9.86%
EBIT to Interest (avg)
0.93
Debt to EBITDA (avg)
2.51
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.58
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.32%
ROE (avg)
5.66%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
19
Industry P/E
40
Price to Book Value
1.27
EV to EBIT
14.70
EV to EBITDA
8.35
EV to Capital Employed
1.22
EV to Sales
0.62
PEG Ratio
0.10
Dividend Yield
NA
ROCE (Latest)
7.30%
ROE (Latest)
6.78%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
NET SALES(Latest six months)

At Rs 14.23 cr has Grown at 43.02%

PAT(9M)

Higher at Rs 0.84 Cr

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Beryl Drugs
Net Sales - Latest six months
At Rs 14.23 cr has Grown at 43.02%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Profit After Tax (PAT) - Nine Monthly
Higher at Rs 0.84 Cr
than preceding 12 month period ended Sep 2026 of Rs 0.01 cr
MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months

PAT (Rs Cr)